Following FDA Registration of Facility, Agilent Stays Mum on Dx Plans | GenomeWeb

Following FDA Registration of Facility, Agilent Stays Mum on Dx Plans

Jul 07, 2011

This article has been corrected to remove a reference to Affymetrix's CytoScan HD product, which was incorrectly identified as Agilent's product.

NEW YORK (GenomeWeb News) – Will Agilent Technologies become the next big player in the diagnostics space?

Probably not, according to one Wall Street analyst.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Related Articles

Jul 08, 2014

ISI Group Downgrades Bruker to Neutral

Oct 14, 2014

Agilent Shutting Down NMR Business, 300 Layoffs Expected

Sep 22, 2014

Merck KGaA to Buy Sigma-Aldrich for $17B

Mar 21, 2014

People in the News: Jennifer Van Eyk, George Scangos

Premium

Jul 17, 2014

Paced by Life Sciences and Diagnostics Business, Danaher Q2 Revenues Increase 5 Percent

Jun 16, 2014

Seeking Clinical Markets for Mass Specs, Thermo Fisher Registers San Jose Site with FDA